Investigating the role of serotonin-2B receptors in heart disease
Official title: Serotonin-2B receptor in hypertrophic cardiomyopathy
Funded at Vanderbilt University · NIH-11001126 · Data updated 2026-11-12
This study is looking at how certain receptors in the heart might play a role in a serious heart condition called hypertrophic cardiomyopathy (HCM), which can be dangerous for young adults, and it aims to find new ways to help reduce heart scarring and improve heart health.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | January 1, 2024 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $48,974 |
| NIH project number | 5F31HL172640-02 |
| Project ID | NIH-11001126 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with hypertrophic cardiomyopathy, particularly young adults at risk of sudden cardiac events.
✕Less likely to help
Patients with other forms of heart disease or those without a diagnosis of hypertrophic cardiomyopathy may not benefit from this research.
What this research studies
This research focuses on understanding how serotonin-2B receptors contribute to fibrosis in hypertrophic cardiomyopathy (HCM), a serious heart condition that can lead to sudden death in young adults. The study aims to explore the cellular mechanisms involved and assess the potential of targeting these receptors to reduce fibrosis, which is a key factor in the disease's progression. By using mouse models and analyzing cardiac fibroblasts, the researchers hope to identify new therapeutic strategies that could improve heart function and patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce heart fibrosis and improve the quality of life for patients with hypertrophic cardiomyopathy.
How similar studies have gone: Previous studies have shown promising results in reducing fibrosis through serotonin-2B receptor antagonism in related cardiac conditions, indicating a potential for success in this approach.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Livingston, William Bryan — Vanderbilt University
- Study coordinator: Livingston, William Bryan
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.